![](/images/graphics-bg.png)
Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation
Joint Authors
Gräger, Nikolai
Leffler, Mareike
Gottlieb, Jens
Fuge, Jan
Warnecke, Gregor
Gutzmer, Ralf
Satzger, Imke
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-03-10
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Background.
Nonmelanoma skin cancer (NSMC) is the most common malignancy after organ transplantation.
Lung transplant recipients (LTRs) are particularly prone to develop NMSC as compared to renal or hepatic transplant recipients due to higher dosages of immunosuppression needed.
Everolimus, an immunosuppressant used in organ transplant recipients, is thought to inherit a lower risk for NMSC than calcineurin inhibitors, especially in renal transplant recipients.
It is currently unknown whether this also applies to LTRs.
Objectives.
To determine risk factors for NMSC and precancerous lesions after lung transplantation (LTx) and to characterize the effect of everolimus-based regimens regarding this risk.
Materials and Methods.
90 LTRs and former participants of the interventional trial “Immunosuppressive Therapy with Everolimus after Lung Transplantation”, who were randomized to receive either an everolimus- or mycophenolate mofetil- (MMF-) based regimen, were enrolled and screened in this retrospective, single-center cohort study.
Results.
After a median follow-up of 101 months, we observed a prevalence of 38% for NMSC or precancerous lesions.
33% of the patients continuously receiving everolimus from LTx to dermatologic examination compared to 39% of all other patients, predominantly receiving an MMF-based regimen, were diagnosed with at least one NMSC or precancerous lesion (P=.66).
Independent risk factors for NMSC or precancerous lesions after LTx were male sex and duration of voriconazole therapy.
Conclusion.
NMSC or precancerous lesions were very common after LTx, and risk factors were similar to previous reports on LTRs.
Everolimus did not decrease this risk under the given circumstances of this study.
Patients should be counseled regarding their risk, perform vigorous sunscreen, and undergo regular dermatological controls, regardless of their immunosuppressive regimen.
American Psychological Association (APA)
Gräger, Nikolai& Leffler, Mareike& Gottlieb, Jens& Fuge, Jan& Warnecke, Gregor& Gutzmer, Ralf…[et al.]. 2019. Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation. Journal of Skin Cancer،Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1191936
Modern Language Association (MLA)
Gräger, Nikolai…[et al.]. Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation. Journal of Skin Cancer No. 2019 (2019), pp.1-11.
https://search.emarefa.net/detail/BIM-1191936
American Medical Association (AMA)
Gräger, Nikolai& Leffler, Mareike& Gottlieb, Jens& Fuge, Jan& Warnecke, Gregor& Gutzmer, Ralf…[et al.]. Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation. Journal of Skin Cancer. 2019. Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1191936
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1191936